Venture capital fund · 30 deals
Venture fund backing early-stage deep tech and life science companies
Brisbane, QLD
Every published round Uniseed took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Uniseed has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Agerris | 10 Apr 2019, Seed | 1 | 1 | |
| Analog Quantum Circuits | 30 Oct 2023 | 2 | 0 | |
| Aravax | 28 Jan 2024, Series B | 1 | 0 | |
| Celosia Therapeutics | 8 Oct 2025, Series A | 1 | 1 | |
| Currus Biologics | 5 Jul 2021, Series A | 1 | 0 | |
| Deteqt | 4 Aug 2026, Seed | 1 | 0 | |
| Diraq | 25 Jun 2024, Series A | 2 | 0 | |
| ENA Respiratory | Antiviral nasal spray to prevent severe respiratory viral infections | 27 Sep 2020, Series A | 3 | 1 |
| Facet Amtech | 26 Aug 2026, Seed | 1 | 1 | |
| Ferronova | 31 Aug 2020, Series A | 3 | 2 | |
| Fibrotech | 10 Feb 2009, Series A | 1 | 0 | |
| Hatchtech | 8 Dec 2008, Grant | 1 | 0 | |
| Kinoxis Therapeutics | 12 Aug 2024, Series B | 2 | 0 | |
| Morse Micro | 31 May 2019, Series A | 4 | 0 | |
| OccuRx | Online casino platform offering slots and table games | 9 Sep 2022 | 1 | 1 |
| PlasmaLeap Technologies | Modular plants for local production of fertilisers and fuels | 4 Aug 2026, Series A | 1 | 0 |
| R2Crete | 1 Oct 2026, Pre-seed | 1 | 0 | |
| Spinifex Pharmaceuticals | Jul 2005 | 2 | 0 | |
| xCystence Bio | 30 Mar 2026, Pre-seed | 1 | 1 |
Investors that coverage says has money in a fund Uniseed runs. This is a stake in the fund, not in any company the fund has backed.
Companies Uniseed has backed that another company then bought. An exit for the holding, not a deal Uniseed did.
| Company | Bought by | Kind | Announced | Price |
|---|---|---|---|---|
| OccuRx | CERTA TherapeuticsTreatment of fibrotic diseases | Acquisition | 19 Dec 2024 | - |
| Spinifex Pharmaceuticals | Novartis International | Acquisition | 29 Jun 2015 | $200m+ |
| Spinifex Pharmaceuticals | Novartis | Acquisition | 29 Jun 2015 | $700m |
| Fibrotech | Shire plc | Acquisition | 2014 | US$75m ($85.6m) |
| Name | Role | Sources |
|---|---|---|
| Jeffrey Bourne | Investment Manager, Technology (Melbourne) | Uniseed, Dealroom, Startup Daily, Uniseed team page |
| Natasha Rawlings | Investment Manager | Startup Daily |
| Dr John Kurek | Investment Director | - |
| David Miles AM | Former Chairman Innovation Australia and Chairman Legal Super (Independent Chairman) (former) | Startup Daily, Uniseed team page |
| Dr Dr Alastair Hick | Chief Executive Officer | Uniseed |
| Dr Peter Devine | CEO (former) | Startup Daily (Wed 29 Oct 2025), Startup Daily (Tue 20 May 2025), kinoxistherapeutics.com, Startup Daily (Wed 15 Nov 2023), Startup Daily (Fri 25 Mar 2022), Brandon Capital portfolio (Mon 28 Sep 2020), Brandon BioCatalyst portfolio (Mon 28 Sep 2020), Brandon Capital portfolio (Mon 28 Sep 2020), Brandon BioCatalyst portfolio (Mon 28 Sep 2020), OneVentures portfolio, GBS Ventures, SmartCompany |
| Dr Leanna Read | Board Member | @AuManufacturing |
Stories naming Uniseed. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Sydney quantum company Diraq has reached the last stage of a US defence quantum program, securing US$51 million with more possible, alongside mentions of PsiQuantum, IonQ and Quantinuum milestones.
Also Forbes Australia
A University of Melbourne spinout has raised pre-seed capital from Uniseed and the university's Genesis fund to build a pilot plant turning waste concrete into low-carbon aggregates and cement replacement.
Also Startup Daily·Dealroom·SmartCompany·Startup Daily·This Week in Australian Startups
Weekly roundup reporting Australian startup funding rounds and government grants, a venture fund close, agreed acquisitions, an IPO pricing, a collapse, plus executive hires and AI policy developments.
Roundup of three Australian raises: Skopos Bio's $12m seed for targeted cancer radiopharmaceuticals, Trendspek's $6m for infrastructure condition AI, and R2Crete's $750,000 pre-seed for concrete recycling.
Also Startup Daily·This Week in Australian Startups·Cut Through Venture
America's medicines regulator has approved Currus Biologics to begin human trials of CUR-001, its solid-tumour CAR T-cell therapy combination, with dosing expected from early 2027.
Australian biotech Currus Biologics has won US regulator clearance to begin human testing of its lead cancer therapy, CUR-001; the company's backers include Brandon Capital, Main Sequence and Uniseed.
Australian biotech Currus Biologics has won US regulatory clearance to begin human testing of its lead cancer therapy, CUR-001, combining an antibody platform with CAR T cells for solid tumours.
Weekly roundup recording a dozen raises and acquisitions, Firmus's scheduled float, a new $50m venture fund, a founder share sale, grant winners, an accelerator intake, and an AI agent's government breach.
Also DealStreetAsia·Dealroom·This Week in Australian Startups·AFR Technology·AFR Technology·Startup Daily·AFR Technology·AFR Technology·ABC News Technology·iTnews
Melbourne dementia drug developer Kinoxis secured $6.75 million equity led by Main Sequence plus a $2.5 million Medical Research Future Fund grant via CUREator+, funding trials of its agitation and pain drug candidates.
Melbourne biotech ENA Respiratory has begun dosing participants in the second part of its Phase IIa trial of INNA-051; its investor lineup, past government funding awards and BLUE KNIGHT alumni status are recapped.
Weekly roundup: Blackbird confirms a record fund close and Galileo reaches a first close, Genesis merges with Proudi, IREN secures massive debt, and several startups report raises, grants and program wins.
Main Sequence explains its decision to back Facet Amtech again alongside Uniseed in a $3 million round, funding the startup's water-based ammonia catalyst work and its first pilot plant.
Also AgFunderNews·Dealroom
The US medicines regulator has granted Fast Track designation to Aravax's peanut-allergy immunotherapy PVX108, easing its development path; the Melbourne-based biotech expects Phase 2 data later in 2026.
Uniseed announces portfolio company BioScout's A$6.75 million round co-led by Demea Sustainable Investment and Astanor to scale its crop disease sensor network internationally.
Sydney cleantech PlasmaLeap raised a US$20m Series A to build fertiliser hubs and expand green ammonia reactor technology for farmers.
xCystence Bio secured pre-seed funding from Uniseed, Monash Ventures, Breakthrough Victoria, and BioCurate to develop targeted protein degraders for treating genetic kidney disease.
Uniseed-backed Australian medtech Q-Sera's blood-clotting tube technology has debuted in Japan via Terumo's VenoJect II launch; the post also credits MRCF and UniQuest Extension Fund as backers.
Melbourne-based ENA Respiratory announced US patent allowances covering its TLR2 agonist platform and a COPD treatment method, strengthening IP protection for its INNA-051 nasal spray candidate now in Phase II testing.
Weekly roundup covering seven raises across the Tasman: Phonely's Series A, Pay.com.au's private placement, and rounds for Atomic Tessellator, Caruso, Deteqt, Clean Slate Clinic and Earthletica, worth roughly $72 million combined.
Also crane.vc
Profile of a Peter Mac spinout advancing solid-tumour cell therapies; recounts its Series A backers, later investment, grant support, and chief executive Sam Cobb's earlier career building and listing AdAlta.
Breakthrough Victoria reports investing in xCystence Bio, a Monash University spinout developing polycystic kidney disease therapies, via its University Innovation Platform alongside BioCurate and UniSeed.
Also Uniseed
Q-Sera's rapid-clotting blood tube technology has gone to market in Japan via Terumo's VenoJect II launch; the Melbourne startup's backers include MRCF, Uniseed and the UniQuest Extension Fund.
Melbourne biotech ENA Respiratory has begun dosing volunteers in a mid-stage trial of its INNA-051 antiviral spray, aimed at limiting common viral illnesses in at-risk groups.
Roundup of seven trans-Tasman raises worth $93.1m this week, headlined by IND Technology's $50m round, with LawVu also acquiring ClauseBase.
Weekly funding roundup covering eight raises totalling over $113 million across aerospace, biotech, materials, health and software, plus a pharmacy firm's acquisition out of administration.
Weekly roundup of eight trans-Tasman startup raises worth a combined $113 million-plus, alongside Joe Zhou's buyout of StrongRoom AI from administrators.
Uniseed chief executive Peter Devine departs after two decades; Monash's Alistair Hick takes over in 2026. The piece recounts Uniseed's fund history and recent stakes in ENA Respiratory and Morse Micro rounds.
Australia's Uniseed venture fund has named Dr Alastair Hick as its chief executive, with the appointment announced as the fund marks 25 years of operation.
Queensland drug developer Lucia Bio added $2 million to its seed round from UniQuest Extension Fund and Uniseed-managed funds, bringing its overall raise to $3 million ahead of a planned Series A.
Weekly roundup detailing new capital for Australian startups Diraq, BrainFish, RecycleSmart, Cohabit and Five Faces, alongside Alumly's undisclosed multimillion-dollar backing from UK investor Mauve Group.
Also Startup Daily
Quantum computing venture Diraq has banked $15 million toward an unfinished round, with earlier backers joined by two new funds, pushing its cumulative funding beyond US$137 million.
UniSuper adds a further $25 million to its backing of Uniseed, reaching $100 million in total support for the university research commercialisation fund; past cheques to quantum and biotech startups are recapped.
Melbourne pharmaceutical company ENA Respiratory has received US$5 million from California's Flu Lab to advance clinical testing of its nasal immune-boosting antiviral candidate INNA-051.
Melbourne biotech Certa Therapeutics has acquired OccuRx, combining two GPR68 fibrosis pipelines founded by Professor Darren Kelly, and says it will seek Series B funding to advance clinical development.
Weekly funding roundup covering eight local companies that together banked $80m, topped by twin $17m Series Bs at Safewill and Fresho, plus Celosia's $16.75m Series A and five smaller rounds.
Also Startup Daily·Startup Daily·Startup Daily·Startup Daily·Startup Daily·Startup Daily·Startup Daily·LaunchVic
Aravax has finished enrolling 95 young patients in its Phase 2 peanut-allergy immunotherapy trial across US and Australian sites, with results expected in the first half of 2026.
Melbourne's ENA Respiratory has won a further US$3.18 million US Defense Department contract to widen its INNA-051 Phase Ib trial to younger adults, extending the US$8.18 million the agency had already committed.
Also Brandon BioCatalyst portfolio·Brandon Capital portfolio·Brandon Capital portfolio·enarespiratory.com
Weekly roundup detailing five raises across Australian and New Zealand startups — Hapana, Kinoxis Therapeutics, Appetise, Bike Matrix and Aglow — worth a combined $38.5 million, naming lead investors and planned expansion for each.